Prognostic significance of nuclear factor-kappaB p105/p50 in human melanoma and its role in cell migration.

Transcriptional factor nuclear factor-kappaB (NF-kappaB) family has been shown to play an important role in tumor pathogenesis and serve as a potential target in cancer therapy. However, it is necessary to clarify the specific functions of NF-kappaB members, which would provide the basis for the selective blockade and reduction of therapeutic side effects resulting from unspecific inhibition of NF-kappaB members. In this study, we explored the role of NF-kappaB p105/p50 in melanoma pathogenesis in vitro and in vivo. We found that the expression of NF-kappaB p105/p50 significantly increased in dysplastic nevi, primary melanoma, and metastatic melanoma compared with normal nevi (P = 0.0004, chi(2) test). Furthermore, NF-kappaB p105/p50 nuclear staining increased with melanoma progression and strong NF-kappaB p105/p50 nuclear staining was inversely correlated with disease-specific 5-year survival of patients with tumor thickness >2.0 mm (P = 0.014, log-rank test). Multivariate Cox regression analysis revealed that nuclear expression of NF-kappaB p105/p50 is an independent prognostic factor in this subgroup. Moreover, we found that up-regulation of NF-kappaB p50 enhanced melanoma cell migration, whereas small interfering RNA knockdown inhibited cell migration. In addition, overexpression of NF-kappaB p50 induced RhoA activity and Rock-mediated formation of stress fiber in melanoma cells. Taken together, our data indicate that NF-kappaB p105/p50 may be an important marker for human melanoma progression and prognosis as well as a potentially selective therapeutic target.

[1]  F. Haluska,et al.  Genetic Alterations in Signaling Pathways in Melanoma , 2006, Clinical Cancer Research.

[2]  D. Toomre,et al.  Lymphocyte transcellular migration occurs through recruitment of endothelial ICAM-1 to caveola- and F-actin-rich domains , 2006, Nature Cell Biology.

[3]  H. Stein,et al.  Elevated NF-κB p50 complex formation and Bcl-3 expression in classical Hodgkin, anaplastic large-cell, and other peripheral T-cell lymphomas , 2005 .

[4]  Alan Hall,et al.  Rho GTPases: biochemistry and biology. , 2005, Annual review of cell and developmental biology.

[5]  M. Falasca,et al.  Class II phosphoinositide 3-kinase defines a novel signaling pathway in cell migration , 2005, The Journal of cell biology.

[6]  A. Richmond,et al.  Role of nuclear factor-κ B in melanoma , 2005, Cancer and Metastasis Reviews.

[7]  Gioacchino Natoli,et al.  Interactions of NF-κB with chromatin: the art of being at the right place at the right time , 2005, Nature Immunology.

[8]  S. Husain,et al.  Constitutive activation of nuclear factor -kB: preferntial homodimerization of p50 subunits in cervical carcinoma. , 2005, Frontiers in bioscience : a journal and virtual library.

[9]  R. Ricciardi,et al.  DNA Binding of Repressor Nuclear Factor-κB p50/p50 Depends on Phosphorylation of Ser337 by the Protein Kinase A Catalytic Subunit* , 2005, Journal of Biological Chemistry.

[10]  M. Martinka,et al.  Prognostic significance of activated Akt expression in melanoma: a clinicopathologic study of 292 cases. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  P. Gassmann,et al.  Role of Tumor Cell Adhesion and Migration in Organ-Specific Metastasis Formation , 2004, Oncology Research and Treatment.

[12]  A. Ridley,et al.  Why three Rho proteins? RhoA, RhoB, RhoC, and cell motility. , 2004, Experimental cell research.

[13]  Ann Richmond,et al.  Augmenting Chemosensitivity of Malignant Melanoma Tumors via Proteasome Inhibition , 2004, Cancer Research.

[14]  F. Meyskens,et al.  Comparative expression of NFkappaB proteins in melanocytes of normal skin vs. benign intradermal naevus and human metastatic melanoma biopsies. , 2004, Pigment cell research.

[15]  M. Javadi,et al.  NF-kappaB binds to a polymorphic repressor element in the MMP-3 promoter. , 2004, Biochemical and biophysical research communications.

[16]  Krister Wennerberg,et al.  Rho and Rac Take Center Stage , 2004, Cell.

[17]  G. Borisy,et al.  Cell Migration: Integrating Signals from Front to Back , 2003, Science.

[18]  R. Pathmanathan,et al.  Activation of nuclear factor-kappaB p50 homodimer/Bcl-3 complexes in nasopharyngeal carcinoma. , 2003, Cancer research.

[19]  Z. Ronai,et al.  Death receptors and melanoma resistance to apoptosis , 2003, Oncogene.

[20]  M. Hendrix,et al.  Molecular plasticity of human melanoma cells , 2003, Oncogene.

[21]  S. Lowe,et al.  Apoptosis and melanoma chemoresistance , 2003, Oncogene.

[22]  R. K Srivastava,et al.  Differential roles of RelA (p65) and c-Rel subunits of nuclear factor kappa B in tumor necrosis factor-related apoptosis-inducing ligand signaling. , 2003, Cancer research.

[23]  Jennifer Y. Zhang,et al.  NF-κB blockade and oncogenic Ras trigger invasive human epidermal neoplasia , 2003, Nature.

[24]  P. Hersey,et al.  Adjuvant therapy for high‐risk primary and resected metastatic melanoma , 2003, Internal medicine journal.

[25]  A. Hall,et al.  Guanine nucleotide exchange factors for Rho GTPases: turning on the switch. , 2002, Genes & development.

[26]  Michael Karin,et al.  NF-κB at the crossroads of life and death , 2002, Nature Immunology.

[27]  D. Granger,et al.  Endothelial Expression of Vascular Cell Adhesion Molecule‐1 Correlates with Metastatic Pattern in Spontaneous Melanoma , 2001, Microcirculation.

[28]  Martin F. Mihm,et al.  Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  L. Ziegler-Heitbrock.  The p50-homodimer mechanism in tolerance to LPS , 2001, Journal of endotoxin research.

[30]  R. Marks,et al.  Epidemiology of melanoma , 2000, Clinical and experimental dermatology.

[31]  G. Salvesen,et al.  ML-IAP, a novel inhibitor of apoptosis that is preferentially expressed in human melanomas , 2000, Current Biology.

[32]  M. Boyano,et al.  Soluble interleukin-2 receptor, intercellular adhesion molecule-1 and interleukin-10 serum levels in patients withelanoma , 2000, British Journal of Cancer.

[33]  Eric S. Lander,et al.  Genomic analysis of metastasis reveals an essential role for RhoC , 2000, Nature.

[34]  A. Marghoob,et al.  Breslow thickness and Clark level in melanoma , 2000, Cancer.

[35]  S. Narumiya,et al.  Signaling from Rho to the actin cytoskeleton through protein kinases ROCK and LIM-kinase. , 1999, Science.

[36]  W. Kiosses,et al.  Regulation of the small GTP‐binding protein Rho by cell adhesion and the cytoskeleton , 1999, The EMBO journal.

[37]  A. Hall,et al.  Rho GTPases and the actin cytoskeleton. , 1998, Science.

[38]  A. Richmond,et al.  Enhanced Degradation of I-κBα Contributes to Endogenous Activation of NF-κB in Hs294T Melanoma Cells , 1997 .

[39]  R. Bravo,et al.  Activation of the nuclear factor-kappaB by Rho, CDC42, and Rac-1 proteins. , 1997, Genes & development.

[40]  David Baltimore,et al.  Embryonic lethality and liver degeneration in mice lacking the RelA component of NF-κB , 1995, Nature.

[41]  G. Rosen,et al.  Characterization of the promoter for vascular cell adhesion molecule-1 (VCAM-1). , 1992, The Journal of biological chemistry.

[42]  A. Jemal,et al.  Cancer Statistics, 2005 , 2005, CA: a cancer journal for clinicians.

[43]  M. Piris,et al.  Progression in cutaneous malignant melanoma is associated with distinct expression profiles: a tissue microarray-based study. , 2004, The American journal of pathology.

[44]  D. Altieri,et al.  Drug Resistance in Melanoma: Mechanisms, Apoptosis, and New Potential Therapeutic Targets , 2004, Cancer and Metastasis Reviews.

[45]  R. Wadhwa,et al.  Cell migration and metastasis as targets of small RNA-based molecular genetic analyses , 2004, Journal of Muscle Research & Cell Motility.

[46]  M. Ballo,et al.  Radiation therapy for malignant melanoma. , 2003, The Surgical clinics of North America.

[47]  Ahmedin Jemal,et al.  Cancer Statistics, 2002 , 2002, CA: a cancer journal for clinicians.

[48]  G. Riethmüller,et al.  De novo expression of intercellular-adhesion molecule 1 in melanoma correlates with increased risk of metastasis. , 1989, Proceedings of the National Academy of Sciences of the United States of America.